Own experience of treatment by epoetin-α (Eralfon®) of chemotherapy induced anemia


Cite item

Full Text

Abstract

Epoetin-α - is a medication, stimulating erythropoiesis. Is currently also used for the treatment of anemia induced by chemotherapy. Patients and methods. 124 patients with various solid tumors and a hemoglobin level <120 g/l received epoetin-α (Eralfon®) 10 000 ME or 12 000 ME three times a week. An evaluation of the increase in hemoglobin level was made, as well as an assessment of the pharmacoeconomic efficacy of various dosage forms. Results. It was noted that during chemotherapy with platinum, the hemoglobin level significantly increases with the use of an Eralfon® 12 000 ME. For patients weighing <70 kg, it is economically advantageous to use Eralfon® 10 000 ME, for patients ≥70 kg - Eralfon® 12 000 ME. The safety profile of both dosages is quite favorable.

About the authors

S A Bolshakova

Russian Scientific Center of Roentgenoradiology of the Ministry of Health of the Russian Federation

Email: bolshakovasvetlana@rambler.ru
канд. мед. наук, ст. науч. сотр. группы противоопухолевой лекарственной терапии научно-исследовательского отд. инновационных технологий радиотерапии и химиолучевого лечения злокачественных новообразований ФГБУ РНЦРР 117997, Russian Federation, Moscow, ul. Profsoiuznaia, d. 86

Yu M Bychkov

Russian Scientific Center of Roentgenoradiology of the Ministry of Health of the Russian Federation

канд. мед. наук, зав. дневным стационаром ФГБУ РНЦРР 117997, Russian Federation, Moscow, ul. Profsoiuznaia, d. 86

M V Kazarova

Russian Scientific Center of Roentgenoradiology of the Ministry of Health of the Russian Federation

врач-онколог дневного стационара ФГБУ РНЦРР 117997, Russian Federation, Moscow, ul. Profsoiuznaia, d. 86

References

  1. Groopman J.E, Itri L.M. Chemotherapy - induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91 (19): 1616-34.
  2. Rodgers G.M, Becker P.S, Blinder M et al. Cancer - and chemotherapy - induced anemia. J Natl Copmr Canc Netw 2012; 10 (5): 628-53.
  3. Wood P.A., Hrushesky W.J. Cisplatin - associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95 (4): 1650-9.
  4. Bohlius J, Weingart O, Trelle S, Engert A. Cancer - related anemia and recombinant human erythropoietin - an update overview. Nat Clin Pract Oncol 2006; 3 (3): 152-64.
  5. Spivak J.L. The anemia of cancer: death by thousand cuts. Nat Rev Cancer 2005; 5 (7): 543-55.
  6. Miller C.B, Jones R.J, Pinatadosi S et al. Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990; 322 (24): 1689-92.
  7. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28 (2 Suppl. 8): 7-14.
  8. Van Belle S.J-P, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003; 47 (1): 1-11.
  9. Blomer J-U, Dunst J, Harrison L et al. Cancer - related anemia: biological findings, clinical implications and impact on quality of life. Oncology 2005; 68 (Suppl. 1): 12-21.
  10. Caro J.J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91 (12): 2214-21.
  11. Nissman B, Barak V, Hubert A et al. Prognostic factors for survival in metastatic breast cancer during first - line paclitaxel chemotherapy. Anticancer Res 2003; 23 (2C): 1939-42.
  12. Hauser C.A, Stockler M.R, Tattersall M.H.N. Prognostic factors in patients with recently diagnosed incurable cancer: a systemic review. Support Care Cancer 2006; 14 (10): 999-1011.
  13. Klein H.G, Spahn D.R, Carson J.L. Red blood cell transfusion in clinical practice. Lancet 2007; 379 (9585): 415-26.
  14. Broudy V.C, Lin N, Brice M et al. Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991; 77: 2583-90.
  15. Witthuhn B.A, Quelle F.W, Silvennoinen O et al. JAK2 associated with erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74: 227-36.
  16. Huang L.J, Constantinescu S.N, Lodish H.F. The N - terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001; 8: 1327-38.
  17. Jelkmann W, Bohlius J, Hallek M et al. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
  18. Bennett C.L, Silver S.M, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer - related anemia. JAMA 2008; 299 (8): 914-24.
  19. European Medicines Agency. Neorecormon. Available from: http:www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000116/human_med_0000921.jsp&mid=WC0b01ac058001d124.
  20. Rizzo J.D, Somerfield M.R, Hagerty K.L et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology. American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26 (1): 132-49.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).